Additional File 3: Extract from case study on the impacts from Tak Lee’s Asthma UK’s Professorial Chair funding: contribution to the development of anti-leukotriene medicines and the treatment of aspirin-sensitive asthma.

Tak Lee was appointed as Asthma UK Professorial Chair in 1988. As part of the mission for his chair he proposed a programme of human work on leukotrienes for which he was already receiving some project funding from Asthma UK. Pioneering work on leukotrienes, molecules that are important mediators of asthmatic responses, had been conducted by Professor Bengt Samuelson, who subsequently received the Nobel Prize. Significant contributions in this field were also made for many years by Professor Frank Austen at Harvard [1,2], the late Professor Priscilla Piper and Professor E. J. Corey, who also received the Nobel Prize. When Lee was a research fellow at Harvard from 1982-4 he worked on leukotrienes with some leading researchers, including Austen, and co-authored a series of well-cited articles on research conducted in Austen’s lab. For example, Lee et al. (1985) [3] has been cited over 1,000 times.

By the mid-1980s major breakthroughs had been made in this area, but there were still some unresolved issues Lee wanted to address and, furthermore, into the 1990s pharmaceutical companies had failed to make an effective anti-leukotriene therapy. Ian Rodger from Merck later wrote that as a consequence of the early failures, ‘many people began to question the putative role of leukotrienes in asthma.’ [4] Lee’s long-term Professorial Chair funding provided the basis for him to conduct a long-running programme of research in this field for which he also drew in continuing project funding from Asthma UK, as well as from the MRC and the Wellcome Trust. Lee’s research covered various areas in which he made significant breakthroughs, in particular in relation to leukotriene E4 (LTE4). He and his colleagues were the first team to show the important role of leukotrienes in mediating aspirin-sensitive asthma as reported in a paper by Christie et al. (1991) [5], which reported on assessing urinary LTE4 levels as a measure of global CysLT4 production in aspirin-sensitive patients. Later the same year, the team showed that experimental leukotriene antagonists (that were then still some way from being commercially available) can significantly protect against aspirin-induced symptoms in people with aspirin-sensitive asthma [6]. In 1993 Lee co-authored a paper - cited over 350 times - showing, in vivo, for the first time in humans that LTE4, which is the most stable leukotriene in the body, had an inflammatory effect because it attracted leukocytes, especially eosinophils [7]. It, therefore, had implications for the potential role of drugs that were being developed because it indicated that the potential benefits from leukotriene receptor antagonists could be greater than had previously been considered.
In terms of a health gain, Lee’s stream of research was the first to identify a group of patients, aspirin-sensitive asthmatics, for whomLTRAs (leukotriene receptor antagonists) are most appropriate. This was not known at the time the medicine development programme started. Furthermore, this stream of research has been used in documents and articles promoting the use of LTRAs, including an early editorial in the BMJ [8] and a recommendation from the Royal College of Physicians [9]. Therefore, it is appropriate to say that the work of Lee and colleagues should share, along with that of other key researchers, some of the credit for the health gain that is resulting from the use of LTRAs. There are undoubtedly some groups for whom there will be a substantial health gain from using LTRAs as opposed to other medicines. In 2009 O’Byrne et al. [10] argued that there are two situations in which LTRAs ‘might have particular advantages over other medicines for asthma treatment.’ One is for aspirin-sensitive asthma and on this topic the first reference O’Byrne et al. give is to the second 1991 paper by Christie et al. [6] In addition to those groups, very large numbers of people in countries such as the USA and Japan use LTRAs. Most commentators accept that there are health gains for them compared to not using medicine, but there are debates about the most effective treatment for general use.

References